[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sglt2-inhibitors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sglt2-inhibitors":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619978","phase-4-ccta-evaluation-of-sglt2i-related-pericoronary-fat-changes-in-non-diabetic-acs-patients-without-hf-100619978",false,"NCT07351643","CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","Assessment of the Effects of SGLT2 Inhibitors on Pericoronary Fat in Non-diabetic ACS Patients Without Heart Failure Using CCTA","DAPA-PCAT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina)\n3. Undergoing percutaneous coronary intervention (PCI)\n4. Presence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment)\n5. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior or current diagnosis of diabetes mellitus\n2. Prior or current diagnosis of chronic heart failure\n3. Treatment with any SGLT2 inhibitor within 4 weeks prior to enrollment\n4. Severe hepatic impairment\n5. History of recurrent urogenital infections\n6. Known allergy or intolerance to SGLT2 inhibitors\n7. Pregnancy or breastfeeding\n8. Systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg\n9. Severe chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n10. Current participation in another interventional clinical trial\n11. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), can reduce coronary artery inflammation in people with acute coronary syndrome (ACS) who do not have diabetes or heart failure.\n\nCoronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.\n\nThe main questions it aims to answer are:\n\n* Does dapagliflozin lower coronary artery inflammation as measured by FAI?\n* Does dapagliflozin slow the progression of coronary plaques?\n\nResearchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention (PCI) for ACS\n* Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone\n* Have a follow-up CCTA scan at 6 months after randomization\n* Have blood tests at the time of PCI, at randomization, and at 6 months after randomization\n* Receive follow-up phone calls at 3 and 6 months after randomization",[27,28],"ACS (Acute Coronary Syndrome)","SGLT2 Inhibitors",[30,31,32,33,34],"Fat attenuation index","SGLT2 inhibitors","Pericoronary adipose tissue","Residual inflammatory risk","Coronary CT angiography","NOT_YET_RECRUITING","2026-01-12",{"date":38,"type":39},"2026-01-20","ACTUAL",{"date":41,"type":21},"2026-02-25",{"date":43,"type":21},"2026-12-30",{"name":45,"class":46},"Shenyang Northern Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100611197","cardiovascular-and-renal-endpoints-with-flozins---an-observational-prospective-study-in-ckd-hfpef-patients-100611197","NCT07237451","Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients","CARE FOR CKD H","Inclusion Criteria:\n\n* age\\>18 years;\n* ejection fraction \\> 40;\n* patients with CKD stage 3-4 (eGFR between 15-60 mL\u002Fmin\u002F1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic;\n* age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.\n\nExclusion Criteria:\n\n* eGFR\\\u003C 15 mL\u002Fmin\u002F1.73m2 or patients undergoing dialysis;\n* presence of congenital heart disease, decompensated cirrhosis, pregnancy and active malignancies;\n* coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions);\n* cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers;\n* active systemic infections (due to interference with biomarkers that can give false rise values).",{"count":56,"type":21},200,"OBSERVATIONAL","The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.",[60,61,28,62],"CKD - Chronic Kidney Disease","Heart Failure Preserved Ejection Fraction","Diabetes (DM)",[64,65,66,67,68],"CKD","HFpEF","SGTL2 inhibitors","Biomarkers","PWV","RECRUITING","2025-11-16",{"date":72,"type":39},"2025-11-19",{"date":74,"type":39},"2025-01-08",{"date":76,"type":21},"2027-12-31",{"name":78,"class":46},"Grigore T. Popa University of Medicine and Pharmacy",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100552496","efficacy-of-sglt2-inhibitors-in-adults-with-sepsis-100552496","NCT06473844","Efficacy of SGLT2 Inhibitors in Adults With Sepsis","Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or above\n* New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)\n* Provision of signed and dated informed consent form from participant or surrogate\n* Ability to take and adhere to oral and enteral medication regimen\n* Willingness to comply\n\nExclusion Criteria:\n\n* Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)\n* Impaired renal function\n* Clinically unstable or in refractory hypotension\n* History of ketoacidosis\n* Gastrointestinal surgery or GI absorption \u002F malabsorption disorder\n* Pregnancy\n* Known allergic or hypersensitivity reactions to any SGLT2 inhibitors\n* Treatment with another investigational drug or other interventions within 30 days prior to trial",{"count":87,"type":21},60,[89],"NA","Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:\n\n(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.\n\n(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.",[92,93,28,94,95],"Sepsis","Inflammation","Critically Ill","Organ Dysfunction Syndrome",[31,92,97,94,98],"Inflammatory Markers","Organ dysfunction","2025-03-17",{"date":101,"type":39},"2025-03-19",{"date":103,"type":39},"2025-03-05",{"date":105,"type":21},"2027-02-28",{"name":107,"class":108},"Hospital Authority, Hong Kong","OTHER_GOV",3,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":47},"100475340","phase-2-effect-of-tofogliflozin-on-uacr-compared-to-metformin-hydrochloride-in-diabetic-kidney-disease-truth-dkd-100475340","NCT05469659","Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)","Effect of Tofogliflozin on Urine Albumin-to-Creatinine Ratio Compared to Metformin Hydrochloride in Diabetic Kidney Disease","TRUTH-DKD","Inclusion Criteria:\n\n* Type 2 diabetic patients\n* Patients aged 20 years or older at the time of obtaining consent\n* Patients with HbA1c 6.5 or more and 9.0% or less within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor \u002F metformin)\n* Patients who have been judged by their doctor to need a diabetic drug when they are first seen, or who have already taken a diabetic drug and have decided that it is necessary to add one diabetic drug.\n* Patients who have been receiving RAS inhibitors (ARB, ARNI, ACE inhibitors, direct renin inhibitors) for 4 weeks or longer\n* Patients with eGFR of 30 or more (mL \u002F min \u002F 1.73m2) within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor \u002F metformin)\n* Patients with urinary albumin \u002F creatinine ratio (UACR) of 30 or more and less than 2000 (mg \u002F gCr) (4 weeks or more without taking SGLT2 inhibitor \u002F metformin) within 13 weeks before obtaining consent Evaluate by inspection value)\n* Patients for whom written consent was obtained based on the patient's free will after receiving sufficient explanation for participation in this study\n\nExclusion Criteria:\n\n* Patients receiving treatment with SGLT2 inhibitor or metformin within 13 weeks before obtaining consent\n* Dialysis patient\n* Patients with a history of severe hypoglycemia\n* Patients with hypersensitivity to SGLT2 inhibitor or metformin\n* Pregnant women, lactating patients, and patients who wish to raise children\n* Patients with BMI of 35 kg \u002F m2 or more based on the latest measured values within 13 weeks before obtaining consent\n* Patients who are contraindicated for the study drug\n* Other patients who the attending physician deems inappropriate as a subject","20 Years",{"count":120,"type":21},120,[122],"PHASE2","This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with chronic kidney disease (CKD).",[125,126,127],"T2DM (Type 2 Diabetes Mellitus)","Metformin","SGLT2-Inhibitors","2022-07-21",{"date":130,"type":39},"2022-07-22",{"date":132,"type":39},"2021-09-22",{"date":134,"type":21},"2026-10-30",{"name":136,"class":46},"Shinshu University"]